title: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.
abstract: Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck, and non-small cell lung cancer. However, due to the relatively recent addition of biologic compounds to the therapeutic arsenal, information related to adverse reactions is less well known than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated as the most frequent side effect cited during cetuximab therapy for malignancy; however, other effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead to significant morbidity and mortality. The purpose of this review is to compile the various pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to compare the incidence of these adverse reactions to standard therapies.
authors.affiliation: Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA. jhoag@drexelmed.edu
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Hoag
authors.forename: Aimel
authors.initials: A
authors.lastname: Azizi
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Doherty
authors.forename: Jason
authors.initials: J
authors.lastname: Lu
authors.forename: Rudolph E
authors.initials: RE
authors.lastname: Willis
authors.forename: Mark E
authors.initials: ME
authors.lastname: Lund
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000473:pathology; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab
references.citation: Expert Opin Drug Saf. 2007 Mar;6(2):175-82
references.pmid: 17367263
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8786-93
references.pmid: 16246975
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2171-7
references.pmid: 17538161
references.citation: J Clin Oncol. 2008 May 10;26(14):2311-9
references.pmid: 18390971
references.citation: N Engl J Med. 2008 Sep 11;359(11):1116-27
references.pmid: 18784101
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3234-43
references.pmid: 11432891
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5568-77
references.pmid: 16009950
references.citation: Br J Cancer. 2008 Aug 5;99(3):455-8
references.pmid: 18665167
references.citation: J Korean Med Sci. 2007 Sep;22 Suppl:S98-S103
references.pmid: 17923763
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8646-54
references.pmid: 16314626
references.citation: Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):391-5
references.pmid: 17980508
references.citation: Ann Oncol. 2007 Feb;18(2):305-10
references.pmid: 17079693
references.citation: Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S53-61
references.pmid: 17520582
references.citation: Oncology (Williston Park). 2006 Oct;20(11):1373-82; discussion 1382, 1392-4, 1397
references.pmid: 17112000
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90
references.pmid: 16979839
references.citation: Indian J Cancer. 2007 Apr-Jun;44(2):56-61
references.pmid: 17938482
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2610-6
references.pmid: 15226328
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5578-87
references.pmid: 16009949
references.citation: N Engl J Med. 2007 Nov 15;357(20):2040-8
references.pmid: 18003960
references.citation: Clin Colorectal Cancer. 2008 Jul;7(4):273-9
references.pmid: 18650196
references.citation: Ann Oncol. 2007 Apr;18(4):738-44
references.pmid: 17208931
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9089-96
references.pmid: 16301597
references.citation: Ann Oncol. 2008 Aug;19(8):1442-1449
references.pmid: 18441330
references.citation: JAMA. 2008 Oct 22;300(16):1887-96
references.pmid: 18940975
references.citation: Gynecol Oncol. 2008 Aug;110(2):140-5
references.pmid: 18554700
references.citation: Ann Oncol. 2008 Apr;19(4):734-8
references.pmid: 18272912
references.citation: Nat Biotechnol. 2006 Jul;24(7):769-76
references.pmid: 16841057
references.citation: Cancer. 2008 Jun 15;112(12):2733-9
references.pmid: 18412149
references.citation: Clin Cancer Res. 2001 May;7(5):1204-13
references.pmid: 11350885
references.citation: Ann Oncol. 2008 Apr;19(4):711-6
references.pmid: 18073221
references.citation: Ann Oncol. 2007 Mar;18(3):510-7
references.pmid: 17164226
references.citation: Cancer. 2008 Nov 1;113(9):2512-7
references.pmid: 18816622
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1072-8
references.pmid: 16505426
references.citation: Lancet Oncol. 2008 Jan;9(1):39-44
references.pmid: 18077217
references.citation: Oncology. 2007;72(1-2):105-10
references.pmid: 18025804
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4914-21
references.pmid: 17050875
references.citation: J Clin Oncol. 2005 May 20;23(15):3568-76
references.pmid: 15809453
references.citation: Gynecol Oncol. 2008 Mar;108(3):493-9
references.pmid: 18191993
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2866-72
references.pmid: 16717293
references.citation: Ann Oncol. 2008 Feb;19(2):362-9
references.pmid: 17947225
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5253-8
references.pmid: 17114658
references.citation: J Clin Invest. 2007 Aug;117(8):2051-8
references.pmid: 17671639
references.citation: Radiographics. 2000 Jan-Feb;20(1):83-98
references.pmid: 10682774
references.citation: Cancer. 2007 Aug 1;110(3):581-9
references.pmid: 17583545
references.citation: J Thorac Oncol. 2008 Jun;3(6):648-51
references.pmid: 18520806
references.citation: Ann Oncol. 2008 Jul;19(7):1288-1292
references.pmid: 18349029
references.citation: J Heart Lung Transplant. 2007 Dec;26(12):1340-4
references.pmid: 18096489
references.citation: Clin Breast Cancer. 2006 Aug;7(3):270-7
references.pmid: 16942645
references.citation: J Clin Oncol. 2000 Feb;18(4):904-14
references.pmid: 10673534
references.citation: Lung Cancer. 2010 Jan;67(1):86-92
references.pmid: 19380175
references.citation: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1081-6
references.pmid: 17881150
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5225-32
references.pmid: 18024868
references.citation: Anticancer Res. 2008 Jul-Aug;28(4C):2459-67
references.pmid: 18751435
references.citation: Br J Cancer. 2006 Mar 27;94(6):792-7
references.pmid: 16508634
references.citation: J Clin Oncol. 2007 Dec 20;25(36):5777-84
references.pmid: 18089875
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: Lancet. 2009 May 2;373(9674):1525-31
references.pmid: 19410716
references.citation: Clin Colorectal Cancer. 2006 Mar;5(6):422-8
references.pmid: 16635281